City of Hope

City of Hope, a NCI-designated Comprehensive Cancer Center

Page Title

Skip Navigation

Global Navigation



Border Border
  
Click here to login to Secure Web Site   (authorized users only)  
  
Search results:  44  Clinical trial(s) found  (Page 1 of 2 )
Results per page: 25 50 100 All 1-25 Trials Jump to page:

The following studies are available for Brain and Nervous System Cancer:
COH Protocol Number: 13459 ClinicalTrials.gov Number: NCT01898273

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  Phase 2, Open-Label, Imaging Trial of I-124-CLR1404 in Patients with Newly Diagnosed or Recurrent Glioblastoma

COH Protocol Number: 13418 ClinicalTrials.gov Number: NCT02014844

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  An Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of Aldoxorubicin in Subjects with Unresectable Glioblastoma Whose Tumors Have Progressed Following Prior Treatment with Surgery, Radiation and Temozolomide

COH Protocol Number: 13401 ClinicalTrials.gov Number: NCT02015819

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination with Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas

COH Protocol Number: 13140 ClinicalTrials.gov Number: NCT01096368

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACNS0831:Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma ages 1-21 years

COH Protocol Number: 13123 ClinicalTrials.gov Number: NCT00916409

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Prospective, Multi-Center Trial of NovoTTF-100A Together with Temozolomide Compared to Temozolomide Alone in Patients with Newly Diagnosed GBM

COH Protocol Number: 13116 ClinicalTrials.gov Number: NCT01156584

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase I Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients with Recurrent High Grade Glioma

COH Protocol Number: 12242

Principal Investigator: Jana Portnow, MD
Sponsor: Institutional

Title:  An Intracerebral Microdialysis Study in Patients with Recurrent High Grade Gliomas Being Treated with TOCA 511 and TOCA FC

COH Protocol Number: 11320 ClinicalTrials.gov Number: NCT01627535

Principal Investigator: Neal Prakash, MD, PhD
Sponsor: Institutional

Title:  Feasibility of Intraoperative Optical Imaging and Spectroscopy in Brain Tumors

COH Protocol Number: 11180 ClinicalTrials.gov Number: NCT00045968

Principal Investigator: Jana Portnow, MD
Sponsor: Industrial

Title:  A Phase III Clinical Trial Evaluating DCVax-Brain, Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen for the Treatment of Glioblastoma Multiforme

COH Protocol Number: 08138

Principal Investigator: Ellie Maghami, MD
Sponsor: Institutional

Title:  City of Hope Head and Neck Database Using the American Head and Neck Society Otobase

COH Protocol Number: 07185

Principal Investigator: Smita Bhatia, MD
Sponsor: NCI Approved External Peer Review

Title:  Childhood Cancer Survivor Study

COH Protocol Number: 02079 ClinicalTrials.gov Number: NCT00026312

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL0032: Phase III Randomized Study Of Chimeric Antibody 14.18 (CH14.18) In High Risk Neuroblastoma Following Myeloablative Therapy And Autologous Stem Cell Rescue

COH Protocol Number: 01094

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ANBL00B1: Neuroblastoma Biology Studies

The following studies are available for many cancer types, including Brain and Nervous System Cancer:
COH Protocol Number: 14161 ClinicalTrials.gov Number: NCT02250157

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  A Dose-regimen Finding Study to Evaluate Safety, Tolerability, Pharmacokinetics and Activity of Oratecan in Subjects with Advanced Malignancies

COH Protocol Number: 14154

Principal Investigator: Saro Armenian, DO
Sponsor: Institutional

Title:  Assessment of a Novel iPhone®-based Platform for Early Detection of Cardiac Dysfunction in Childhood Cancer Survivors at Risk for Anthracycline-related Heart Failure

COH Protocol Number: 14123 ClinicalTrials.gov Number: NCT01817075

Principal Investigator: Anna Pawlowska, MD
Sponsor: Cooperative Group

Title:  COG ACCL1034: Impact of Cleansing with Chlorhexidine Gluconate (CHG) on Reducing Central Line Associated Bloodstream Infection (CLABSI) and Acquisition of Multi-drug Resistant Organisms (MDRO) in Children with Cancer or Those Receiving Allogeneic Hematopoietic Cell Transplantation (HCT)

COH Protocol Number: 13431 ClinicalTrials.gov Number: NCT01868022

Principal Investigator: Karen Reckamp, MD
Sponsor: Industrial

Title:  Multi-arm, Non-randomized, Open-Label Phase IB Study to Evaluate GSK3052230 in Combination with Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects with Solid Malignancies and Deregulated FGF Pathway Signaling

COH Protocol Number: 13398

Principal Investigator: Jeffrey Wong, MD
Sponsor: Institutional

Title:  A Pilot Study of Functional MRI to Evaluate Neurocognition After Brain Radiation

COH Protocol Number: 13385 ClinicalTrials.gov Number: NCT02077218

Principal Investigator: Saro Armenian, DO
Sponsor: Institutional

Title:  Assessment of Coronary Artery Disease in Asymptomatic Survivors of Allogeneic Hematopoietic Cell Transplantation (HCT): A Pilot Feasibility Study

COH Protocol Number: 13275

Principal Investigator: Anna Pawlowska, MD
Sponsor: Non-NCI Approved External Peer Review

Title:  Predictive Biomarkers For Pediatric Chronic Graft-Versus­-Host Disease

COH Protocol Number: 13242 ClinicalTrials.gov Number: NCT01877811

Principal Investigator: Marwan Fakih, MD
Sponsor: Industrial

Title:  An Open-Label, Phase 1/Phase 2, Single-Agent Study of CEP-32496 in Patients with Advanced Solid Tumors in Phase 1 and in Patients with Advanced Melanoma and Metastatic Colorectal Cancer with BRAF Mutation in Phase 2

COH Protocol Number: 13238 ClinicalTrials.gov Number: NCT01834937

Principal Investigator: Jeffrey Wong, MD
Sponsor: Industrial

Title:  A Post Approval Registry: ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

COH Protocol Number: 13237 ClinicalTrials.gov Number: NCT01833806

Principal Investigator: Jeffrey Wong, MD
Sponsor: Industrial

Title:  A Phase IV Post Approval Clinical Study of ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

COH Protocol Number: 13193 ClinicalTrials.gov Number: NCT01828775

Principal Investigator: Betty Ferrell, PhD
Sponsor: NCI Approved External Peer Review

Title:  Integration of Palliative Care for Cancer Patients on Phase I Trials

COH Protocol Number: 13128 ClinicalTrials.gov Number: NCT01817335

Principal Investigator: Jeanelle Folbrecht, Ph.D
Sponsor: Institutional

Title:  Pilot Study of Psycho-Educational Group for Young Adults (YA) on Treatment: Impact on Knowledge, Distress, and Satisfaction

 
Results per page: 25 50 100 All 1-25 Trials Jump to page:

 
 
  
NCI CCC LogoCity of Hope, An NCI-designated Comprehensive Cancer Center, is an innovative biomedical research, treatment and educational institution dedicated to the prevention and cure of cancer and other life-threatening illness.
Best Of logoCity of Hope has been named one of "America's Best Hospitals" in cancer and gynecology by U.S. News & World Report. Read more here...
NCI CCC LogoThe National Comprehensive Cancer Network (NCCN), a not-for-profit alliance of 21 of the world’s leading cancer centers, is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
Best Of logoWe subscribe to the HONcode of the Healthcare on the Net Foundation.